Latest DecisionDx-UM Stories
Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic therapy. With the hope of predicting patient survival, researchers at the University of Mississippi Medical Center in Jackson and at the Ohio State University Comprehensive Cancer Center in Columbus analyzed CT images and clinical data from 46 patients with metastatic melanoma that were treated...
45 percent of Treated Lesions Demonstrated a Durable Response Of At Least 6 Months SAN DIEGO, March 25, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCQB: ONCS) - a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors - announced positive, durable response results in an update on interim data from its Phase II metastatic melanoma trial. The data was presented at the HemOnc Today Melanoma and Cutaneous Malignancies...
HOUSTON, Feb. 14, 2013 /PRNewswire/ -- Castle Biosciences Inc., a leading developer of prognostic tests for rare cancers, announced today the launch of MyUvealMelanoma.com, a website created to educate newly diagnosed patients, their families and healthcare providers about the most common form of eye cancer. MyUvealMelanoma tells the story of this disease, its treatment and the importance of prognostic testing, through the experience of patients who recently faced this devastating...
SAN DIEGO, Nov. 15, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announces positive preliminary results from a Phase II trial investigating the use of ImmunoPulse in metastatic melanoma patients at the 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress. This preliminary interim analysis of 13 out of 25 patients...
SAN DIEGO, Sept. 25, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that it has established the University of Washington (UW) as the second enrolling site for its Phase II metastatic melanoma clinical trial (OMS-I100). Investigational Review Board (IRB) approval has been received by UW, and investigators are actively recruiting for this...
Melanoma Network of Canada hopeful with decision by Ontario and Saskatchewan to provide Yervoy to treat metastatic melanoma OAKVILLE, ON, Sept. 18, 2012 /CNW/ - The Melanoma Network of Canada is encouraged by the announcement that Ontario and Saskatchewan have agreed to provide access to Yervoy, a new treatment for metastatic melanoma, the most deadly form of skin cancer and is hopeful that other provinces will also make this new treatment available to patients as soon as...
